American College of Cardiology announces late-breaking clinical trials for ACC.25
The American College of Cardiology (ACC) has revealed a full list of the late-breaking clinical trials and clinical research sessions scheduled for the group’s annual meeting, ACC.25.
Late-breaking clinical trials are typically some of the most popular sessions during ACC conferences. Attendees will want to show up on time to secure a good seat.
Coronary artery disease, semaglutide, artificial intelligence, transcatheter aortic valve replacement (TAVR), heart failure and percutaneous coronary intervention are just some of the topics these presentations will cover.
ACC.25 is March 29-31 at the McCormick Place Convention Center in Chicago. Virtual options will be made available for some of these sessions.
The full schedule of late-breaking clinical trials includes:
Late-Breaking Clinical Trials I (Session 102)
Saturday, March 29 / 9:30 – 10:30 a.m. CT / Main Tent, North Hall B
- Primary and Secondary Outcomes of the Women's Ischemia Trial to Reduce Events in Non-Obstructive Coronary Artery Disease
- The Effect of Once-weekly Subcutaneous Semaglutide on Functional Capacity in People With Type 2 Diabetes and Peripheral Artery Disease: Primary Results From the Phase 3b, Randomized, Placebo-Controlled, Double Blind Stride Trial
- Extended Anticoagulant Treatment With a Reduced Versus Full Dose Apixaban in Patients With Cancer-Associated Venous Thromboembolism: The API-CAT Study
ACC Late-Breaking Clinical Trials II (Session 104)
Saturday, March 29 / 1:30 – 2:30 p.m. CT / Main Tent, North Hall B
- Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
- Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- Development and External Validation of a Deep Learning Electrocardiogram Model For Risk Stratification of Coronary Revascularization Need in the Emergency Department
- Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
Late-Breaking Clinical Trials III (Session 105)
Saturday, March 29 / 3 – 4 p.m. CT / Main Tent, North Hall B
- Efficacy of Rivaroxaban Versus Warfarin in Patients With Acute Left Ventricular Thrombus Following Myocardial Infarction: An Open-Label Randomized Controlled Trial RIVAWAR Trial Investigators
- Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients With Coagulopathy — Results From a Phase 3, Randomized, Active-Control Study
- The Main Results of the Phase 3 Reverse-it Trial
- Stratified Randomization Study to Compare Different Duration of Dual-antiplatelet Therapy After Coronary Stenting in Either High or Low Bleeding Risk Population
Late-Breaking Clinical Trials IV (Session 106)
Sunday, March 30 / 8 – 9 a.m. CT / Main Tent, North Hall B
- Comparative Effectiveness of Mobile Integrated Health Versus a Transitions of Care Coordinator in Patients With Heart Failure: Results From the MIGHTy-Heart Trial
- Liberal Fluid Intake Versus Fluid Restriction in Chronic Heart Failure
- The Equiox Study: Evaluating Pulse Oximeter Bias Across a Range of Skin Pigment in Critically Ill Adults
- Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF2) Trial
Late-Breaking Clinical Trials V (Session 107)
Sunday, March 30 / 10 – 11 a.m. CT / Main Tent, North Hall B
- Routine Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation: The British Heart Foundation (BHF) PROTECT-TAVI Trial
- Clinical And Echocardiographic Outcomes Among the First 500 Patients Treated With a Dedicated Transcatheter Aortic Valve For Pure Aortic Regurgitation in the Align-AR Clinical Trial
- 5-year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
- Comparison of Angiography-Derived Fractional Flow Reserve-Guided and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention Strategies: The FLAVOUR II Trial
Late-Breaking Clinical Trials VI (Session 108)
Sunday, March 30 / 11:30 a.m. – 12:30 p.m. CT / Main Tent, North Hall B
- Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The Triluminate Pivotal Trial
- Fractional Flow Reserve Guided Percutaneous Coronary Intervention Compared With Bypass Surgery: Final 5 Year Results of the Fractional Flow Reserve Versus Angiography For Multivessel Evaluation 3 Trial
- Clopidogrel Versus Aspirin For Long-Term Maintenance Monotherapy in Patients With High Ischemic Risk After Percutaneous Coronary Intervention
- Alliance For Secondary Prevention After an Acute Coronary Syndrome
Featured Clinical Research I (Session 109)
Sunday, March 30 / 1:30 – 2:30 p.m. CT / Main Tent, North Hall B
- Pre-Operative Treatment With Digifab Prevents Post-Operative Acute Kidney Injury (AKI) in Patients at High Risk For AKI Undergoing Cardiac Bypass Graft Surgery
- Catheter Ablation vs. Risk Factor Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Study
- An Extended Duration Small-Interfering RNA Targeting Lipoprotein(a): The Alpaca Phase 2 Trial of Lepodisiran With 540 Day Follow-Up
- Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: The Detect AS Trial
Featured Clinical Research II (Session 110)
Sunday, March 30 / 3:30 – 4:30 p.m. CT / Main Tent, North Hall B
- Herzcheck - Mobile CMR to Improve Subclinical Heart Failure Detection in Rural Areas
- A Double Blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients With HFrEF: Principal Results From the CardiAMP-HF Trial
- Early Intra-aortic Balloon Pump in Heart Failure Complicated by Cardiogenic Shock: The Altshock-2 Randomized Clinical Trial
- Health 360x.ai Registry: AI Enabled Equitable Access To Point of Care Decentralized Clinical Trials
Featured Clinical Research III (Session 111)
Sunday, March 30 / 5 – 6 p.m. CT / Main Tent, North Hall B
- Modified Application of Cardiac Rehabilitation For Older Adults (MACRO)
- Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States
- Lifetime Benefit by Control of Modifiable Risk Factors
- Cardiac Arrest During Long-Distance Running Races: 2010-2023
Featured Clinical Research IV (Session 112)
Monday, March 31 / 9 – 10 a.m. CT / Main Tent, North Hall B
- Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, Obesity and Chronic Kidney Disease: The SUMMIT Trial
- Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The EKSTROM Trial
- Effects of Dapagliflozin on Echocardiographic Measures of Cardiac Structure and Function in Patients With Chronic Kidney Disease: The DECODE-CKD Trial
- Effect of Solbinsiran, a Small Interfering RNA Targeting ANGPTL3, on Biomarkers of Major Adverse Cardiovascular Events in Adults With Mixed Dyslipidemia: A Randomized Phase 2 Trial
Clinical and Investigative Horizons I (Session 402)
Monday, March 31 / 9 – 10 a.m. CT / S100bc
- First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of Tn-201, An Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, In Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy
- Artificial Intelligence-Based Quantitative Computed Tomography (AI QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry Confirm2 (Coronary CT Angiography Evaluation For Evaluation of Clinical Outcomes)
- Effect of Berberine Hydrochloride on Visceral and Liver Fat in Non-Diabetic Individuals With Visceral Adiposity
- Artificial Intelligence Empowers Novice Users to Acquire Diagnostic-Quality Echocardiography
- Efficacy and Safety of Sotatercept in High-Risk Patients With Pulmonary Arterial Hypertension: Results From ZENITH Phase 3 Trial
Featured Clinical Research V (Session 113)
Monday, March 31 / 11 a.m. – Noon CT / Main Tent, North Hall B
- New Insights From the Early and Delayed Aortic Valve Replacement Implant Patients: A Sub-Analysis of the Early TAVR Trial
- Alternative Antithrombotic Pathways in Acute Myocardial Infarction With Large Thrombus Burden: A Randomized Trial ARISE-ARMYDA 7
- Efficacy and Safety of Azd0780, an Oral Small Molecule PCSK9 Inhibitor For Treatment of Hypercholesterolemia: Results From a Ph2b Randomized Placebo-Controlled Clinical Trial
- Effectiveness of the 0/1-hour Algorithm For Chest Pain Assessment in Patients Presenting to the Emergency Department: A Multicenter Study in Asian Countries
Late-Breaking Clinical Trial Deep Dive I (Session 418)
Monday, March 31 / 11 a.m. – Noon CT / S100bc
- Get even more insights from key clinical trials presented at ACC.25 and find out what it all means for your patients.
Clinical and Investigative Horizons II (Session 434)
Monday, March 31 / 1 – 2 p.m. CT/ S100bc
- Efficacy and Safety of SHR-1918, an Angiopoietin-like 3 Monoclonal Antibody, in Combination With Lipid-Lowering Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase 2 Trial
- Homogeneous Effects of Intensive Blood Pressure Control in Patients With Various Frailty Status: A Post-hoc Analysis of the Esprit Trial
- Impact of Intravascular Imaging Guidance on Percutaneous Coronary Intervention of Severely Calcified Lesions: The ECLIPSE Trial
- A Randomized Controlled Crossover Study of Cardiologist Reporting of Severe Aortic Stenosis With and Without Assistance From Artificial Intelligence (AI)
- Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Primary Biomarker Analysis From the EARLY TAVR Trial
Late-Breaking Clinical Trial Deep Dive II (Session 450)
Monday, March 31 / 2:30 – 3:30 p.m. CT / S100bc
- Get even more insights from key clinical trials presented at ACC.25 and find out what it all means for your patients.
Michael Walter, Managing Editor
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.